Rai and Binet staging systems are important to predict the outcome of patients with chronic lymphocytic leukemia (CLL) but do not reflect the biologic diversity of the disease nor predict response to therapy, which ultimately shape patients' outcome. We devised a biomarkers-only CLL prognostic system based on the two most important prognostic parameters in CLL (i.e., IGHV 
| I N T R O D U C T I O N
Chronic lymphocytic leukemia (CLL) is characterised by the accumulation of monoclonal CD5
1 B cells with a typical phenotype (i.e., CD19
1 CLL are currently diagnosed in early (Rai stage 0 or Binet stage A) clinical stage, this limiting the prognostic significance of clinical stages as a whole. 4 In addition, clinical stages do not reflect the complex biology of CLL that accounts for its clinical heterogeneity 1 and do not predict response to therapy which is the most important predictor of survival. 5, 6 Recently, a prognostic index called CLL International Prognostic
Index (CLL-IPI), based on the assessment of five variables (i.e., age, beta2 microglobulin, IGHV mutational status, del17p and clinical stage), has been proposed and validated. [7] [8] [9] [10] Of note, the CLL-IPI includes continuous parameters (i.e., age, serum beta-2 microglobulin), gives different weight to the included variables, and separates four prognostic groups (i.e., low-, intermediate-, high-, and very-high), of which the very high-risk group is very small, altogether complicating its applicability. The aim of this study was to simplify the CLL-IPI. 
| M E T H O D S

| R E S U LTS
The main characteristics of the training (Barcelona) series are shown in Table 1 . First, we performed multivariable analyses to confirm that in our series all five covariates included in the CLL-IPI had independent prognostic value in terms of OS. In our hands, both sets of variables (i.
e., age
Binet) confirmed their independent prognostic value (Supporting Information Table I ). Moreover, all CLL-IPI four patient subgroups had a significantly different survival, although the high-and very-high risk groups overlapped, and as in the original description of the CLL-IPI and in external validation series the number of patients in the very high-risk 14 (3) CLL-IPI using Binet staging system Low risk, n (%) subgroup was quite low (2-3% in the Barcelona series) (Supporting Information Figure 1 ).
Next, we identified combinations of biomarkers with significant discriminatory value. The combination of IGHV mutational status 1 FISH-detected genetic aberrations (i.e., del17p, del11q) was found to be able to segregate patients with different TTFT and OS.
Thus, in 524 unselected subjects with CLL from the Barcelona group, TTFT at 5-years was 22% (95% CI:18-28%), 63% (55-70%) and 82% Table II) . Also, patients from the Brno series received chemoimmunotherapy more frequently than those from the training series (45% vs.30%) as initial therapy. All these differences notwithstanding, the two-biomarker prognostic model was fully validated in the Brno series both in terms of TTFT and OS (Supporting Information Figure 2 Figure 3 ). The biomarkers-only CLL prognostic model segregated patients with different TTFT among 337 subjects with stage A CLL from an independent, prospectively collected external series ( Figure 1D ) (c-statistic: 0.67).
Finally, the prognostic model applied to all patients with CLL independently of their age ( Figure 1E ,F) (c-statistic: 0.68).
| DISCUSSION
In the last few decades the management of patients with CLL has substantially improved and, as a result, the median OS of subjects with this form of leukemia has increased from 5-6 years to more than 10 years. To be extensively applicable and clinically actionable prognostic models should be simple and based on standardized, robust and validated parameters. 28, 29 One of the most important, and still unparalleled advances in CLL, is that in this disease IGHV genes can be either mutated ( ͠ 60% of cases) or unmutated ( ͠ 40% of cases), a fact that modulates several important pathogenetic pathways and separates two different forms of disease. While most patients with mutated IGHV genes have indolent disease, favorable biomarkers and good prognosis, those with unmutated IGHV genes tend to have rapidly progressive clinical course, unfavorable biomarkers and short survival. 14, 15 Therefore, the IGHV mutational status is not only a key CLL biologic feature but also a prognostic backbone around which revolve many other outcome indicators, either favorable ("mutated" CLL) or unfavorable ("unmutated" CLL). In turn, del(17p)/TP53 mutations can be found in 5%-50% of patients depending on the study time point, prior therapy and disease characteristics, and predict poor response to chemo (immuno)therapy. 16, 17, 33, 34 The prognostic importance of IGHV mutational status and del(17p) has been highlighted in a recent meta-analysis. 35 Besides, del(11q) includes a minimally deleted region encompassing the ATM gene in 30%-40% of cases and is associated with a short time to treatment, short progression-free-survival, and inferior OS after single agent fludarabine treatment. 36, 37 Del(17p) and del(11q) are considered to define high-risk CLL based on FISH-cytogenetics. 38 Although There is a small proportion of patients with CLL in whom TP53 aberrations can be observed in the absence of del(17p). 30, 37 In the Barcelona's series 3% of patients presented TP53 mutation with no del17p; not surprisingly, these cases did not modify the results of the study (data not shown). Patients receiving targeted therapies (i.e., BCR signal inhibitors, BCL2 antiapoptotic agents), were not well represented in our cohorts and should be investigated. However, there is data showing that IGHV mutational status and del17p are associated with a poorer outcome of patients treated with BCR signal inhibitors. 45, 46 The prognostic model has implications in the management of patients with CLL. While most patients with high-risk disease require early intervention, around 50% of patients with low-risk disease do not 
